| dbo:description
|
- United States Supreme Court case (en)
- справа у Верховному суді США (uk)
|
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageWikiLink
| |
| dbp:arguedate
|
- 0001-04-20 (xsd:gMonthDay)
|
| dbp:argueyear
| |
| dbp:case
|
- Merck KGaA v. Integra Lifesciences I, Ltd., (en)
|
| dbp:cornell
| |
| dbp:courtlistener
| |
| dbp:decidedate
|
- 0001-06-13 (xsd:gMonthDay)
|
| dbp:decideyear
| |
| dbp:fullname
|
- Merck KGaA, Petitioner v. Integra Lifesciences I, Ltd., et al. (en)
|
| dbp:googlescholar
| |
| dbp:holding
|
- The Court held that the use of patented compounds in preclinical studies is protected under § 271 at least as long as there is a reasonable basis to believe that the compound tested could be the subject of an FDA submission and the experiments will produce the types of information relevant to an IND or NDA. (en)
|
| dbp:joinmajority
| |
| dbp:justia
| |
| dbp:lawsapplied
| |
| dbp:litigants
|
- Merck KGaA v. Integra Lifesciences I, Ltd. (en)
|
| dbp:majority
| |
| dbp:oyez
| |
| dbp:parallelcitations
| |
| dbp:prior
| |
| dbp:subsequent
| |
| dbp:uspage
| |
| dbp:usvol
| |
| dbp:wikiPageUsesTemplate
| |
| dct:subject
| |
| rdf:type
| |
| rdfs:label
|
- Merck KGaA v. Integra Lifesciences I, Ltd. (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| foaf:name
|
- Merck KGaA, Petitioner v. Integra Lifesciences I, Ltd., et al. (en)
|
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |